Thymosin Alpha-1
Also Known As: Thymalfasin, Zadaxin, Talpha1, Tα1, Thymosin alpha 1, Thymosin α1, Thymalfasine, Hepatitis thymosin, Immune adjuvant thymosin, TA1, Zadaxin thymosin, Thymosin alpha-1 acetate, Prothymosin fragment, Hepatitis B immune peptide, TA-1, thymalfasin
Thymosin Alpha-1 is a research-grade 28-amino acid peptide targeting TLR2/TLR9 signaling studied in Immunity & Wellness research. It is supplied strictly for in vitro laboratory research use only - not for human or animal consumption, and not FDA-approved.
Evidence Tier: Approved Drug - FDA and/or EMA approved with robust human trial data.
A well-studied immune-modulating peptide approved abroad for hepatitis and as a cancer adjunct.
At A Glance
| Category | Immunity & Wellness |
|---|---|
| Compound Class | 28-amino acid peptide; N-terminal fragment of prothymosin alpha; biological response modifier |
| Molecular Target | TLR2/TLR9 signaling; dendritic cell maturation; T-helper (Th1) polarization; NK cell cytotoxicity; NF-kB immunomodulation |
| Molecular Weight | 3108.3 Da |
| Amino Acid Sequence | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN-OH |
| CAS Number | 62304-98-7 |
| Half-Life | ~2 hours |
| WADA Status | not_listed |
| Evidence Tier | Approved Drug |
Mechanism Of Action
It directly stimulates the action of natural killer cells and T-cells, enhancing the body's cell-mediated immune response to quickly hunt down and eradicate viral infections and rogue cells.
Studied For
- Chronic hepatitis B treatment
- Chronic hepatitis C treatment
- Cancer immune adjunct therapy
- Vaccine adjuvant
- Sepsis / severe infection
- COVID-19 immune support research
- Immunodeficiency models
- HIV / AIDS immune support
- Antifungal immune support
- Malignant melanoma adjuvant
- Lung cancer immune research
- T-cell / NK cell activation
- Dendritic cell maturation
- Toll-like receptor signaling
- Autoimmune modulation
- Gut mucosal immunity
- Chemotherapy immune protection
- immune booster
- T-cell modulation
- viral infection
- autoimmune
- immunomodulator
- Lyme disease
- chronic fatigue
- cancer adjunctive
- vaccine efficacy
Reported Research Findings
The most clinically validated peptide in this group: more than 20 human trials and approval in over 30 countries for hepatitis B and C and as a cancer immune adjunct.
Safety And Handling Notes
Generally well tolerated; injection-site reactions are most common; serious adverse events are uncommon.
Not centrally US FDA or EMA approved (off-label/investigational in the US, subject to FDA compounding action). Caution in transplant immunosuppression and autoimmunity.
Regulatory Status
Approved as thymalfasin in 30+ countries; not US central-approved.
Full Reference Detail
Related Research Guides
Maintained By The Pep Nation Lab Research Team. See Our Editorial Standards And Research Methodology For How This Reference Is Sourced And Reviewed.
This Reference Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption. See The Full Research Disclaimer.